Abstract
Prostate cancer (PCa) is one of the most common malignancies threatening men's health globally. A comprehensive and integrated approach is essential for its early screening, diagnosis, risk stratification, treatment guidance, and efficacy assessment. Radiomics, leveraging multi-parametric magnetic resonance imaging (mpMRI) and positron emission tomography/computed tomography (PET/CT), has demonstrated significant clinical value in the non-invasive diagnosis, aggressiveness assessment, and prognosis prediction of PCa, with substantial potential when combined with artificial intelligence. In genomics, mutations or deletions in genes such as TMPRSS2-ERG, PTEN, RB1, TP53, and DNA damage repair genes (e.g., BRCA1/2) are closely associated with disease development and progression, holding profound implications for diagnosis, treatment, and prognosis. Concurrently, biomarkers like prostate-specific antigen (PSA), novel urinary markers (e.g., PCA3), and circulating tumor cells (CTCs) are widely utilized in PCa research and management. Integrating these technologies into personalized treatment plans and the broader framework of precision medicine allows for an in-depth exploration of the relationship between specific biomarkers and disease pathogenesis. This review summarizes the current research on radiomics, genomics, and biomarkers in PCa, and discusses their future potential and applications in advancing individualized patient care.